Gamma Biosciences takes controlling stake in Mirus Bio

19 May 2021
merger-large

California, USA-based Gamma Biosciences has as agreed to make a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Madison, Wisconsin. Current Mirus shareholders will retain a substantial equity ownership stake in the company.

The transaction will support Mirus’ plans to expand good manufacturing practice (GMP) production and commercialization of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral vectors for gene therapy, as well as further development and commercialization of the platform for in vivo delivery applications

Originally developed for therapeutic delivery of RNA, Mirus LPNCs have been adapted for a wide range of gene delivery applications. Demand for efficient and scalable gene delivery technologies continues to increase as larger volumes of viral vector are required to support the growing number of gene therapies in development.  TransIT® VirusGen and Mirus’ portfolio of additional products and services enable customers at both research and clinical scales achieve cost effective, industry leading functional titers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology